News from alk A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

03 Jun, 2019, 15:38 BST As ALK Prepares to Further Extend Their SLIT-tablet Portfolio, Tablet Formulation is Seen as Key in Delivering Consistent Positive Clinical Trial Results

Zydis® freeze-dried tablet technology used in ALK's SLIT-tablet range makes them faster dissolving than conventional compressed sublingual tablets in ...


03 Jun, 2019, 12:15 BST Targeted Early Treatment With ALK's ACARIZAX® Could Improve Allergic Asthma Treatment, Allergy Congress Hears

ALK's (ALKB:DC / OMX: ALK B / AKABY / AKBLF) sublingual allergy immunotherapy (SLIT) tablet against house dust mite (HDM) allergy ought to have a...


29 Apr, 2019, 10:00 BST The Pollen Season Kicks Off With an Award-winning Pollen App

If you are one of the estimated 5 million in the UK who sneeze and sniffle their way through the pollen season, then help is at hand. A personalised...


07 Jul, 2017, 10:00 BST ALK - Five-year GRAZAX® Asthma Prevention (GAP) Trial Reveals Benefits of Early Treatment Intervention in Children

The disease modifying property of GRAZAX® (SQ® grass SLIT-tablet) resulted in long-term effect on allergic rhinoconjunctivitis (ARC) and prevented...


20 Jun, 2017, 10:00 BST ALK Symposium Reveals Early Treatment is Critical for Respiratory Allergic Disease in Children and Adolescents

Allergic rhinitis has a major impact on children's quality of life Children with allergic rhinitis have an increased risk of developing asthma Early...


03 Mar, 2017, 09:22 GMT ALK Appoints SVP of R&D for North America and International Markets

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced the appointment of Hendrik Nolte, M.D., Med.Sc.D, as Senior Vice President of Research and ...


01 Mar, 2017, 23:36 GMT ALK Announces FDA Approval for its House Dust Mite Sublingual Allergy Immunotherapy Tablet (ACARIZAX® in Europe)

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License...


27 Feb, 2017, 13:46 GMT ALK’s ACARIZAX® Data Results in Significant Change to the GINA Asthma Management Strategy: Sublingual Allergy Immunotherapy (SLIT) Recommended as a Treatment Option in Patients With House Dust Mite Allergic Asthma

ALK (ALKB: DC / OMX: ALK B / AKABY / AKBLF) today announced that for the first time, allergy immunotherapy is now recommended as a treatment option...


14 Jun, 2016, 07:00 BST New Data From GAP Landmark Trial Confirm GRAZAX® Significantly Reduces Asthma Symptoms in Children

Treatment benefit increased over time. In the two years after treatment completion, the estimated risk of experiencing asthma symptoms nearly halved...


13 Jun, 2016, 16:00 BST New Data From GAP Landmark Trial Confirm GRAZAX® Prevents Asthma Symptoms in Children

Treatment benefit increased over time. In the two years after treatment completion, the estimated risk of experiencing asthma symptoms nearly halved...


27 Apr, 2016, 06:00 BST Journal of the American Medical Association Publishes Phase III Data From Allergic Asthma Trial With ALK's House Dust Mite SLIT-tablet, ACARIZAX®

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that The Journal of the American Medical Association (JAMA) has published results from a...


09 Jun, 2014, 14:00 BST ALK Presents Phase III Data on House Dust Mite SLIT-tablet at EAACI Annual Congress in Copenhagen

First sublingual allergy immunotherapy tablet with robust results in allergic rhinitis and allergic asthma. Data supports European regulatory filing...


08 Jun, 2014, 18:00 BST Allergy Experts Address Pivotal Questions in Treatment of Grass Pollen Allergy Sufferers

And highlight a decade of clinical evidence demonstrating long-term efficacy and tolerability of once-daily GRAZAX® SLIT-tablet at EAACI 2014 A group ...